Find Talazoparib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C19H14F2N6O
Molecular Weight
380.4  g/mol
InChI Key
IUEWAGVJRJORLA-HZPDHXFCSA-N

Talazoparib
1 2D Structure

Talazoparib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1(13),5,7,9-tetraen-4-one
2.1.2 InChI
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,25H,1H3,(H,26,28)/t15-,16-/m1/s1
2.1.3 InChI Key
IUEWAGVJRJORLA-HZPDHXFCSA-N
2.1.4 Canonical SMILES
CN1C(=NC=N1)C2C(N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
2.1.5 Isomeric SMILES
CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
2.2 Create Date
2010-03-15
3 Chemical and Physical Properties
Molecular Weight 380.4 g/mol
Molecular Formula C19H14F2N6O
XLogP31.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count2
Exact Mass380.11971542 g/mol
Monoisotopic Mass380.11971542 g/mol
Topological Polar Surface Area84.2 A^2
Heavy Atom Count28
Formal Charge0
Complexity826
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Fareva

Luxembourg

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ESCRS
Not Confirmed
arrow

Fareva

Luxembourg

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
ESCRS
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

02

Hangzhou Longshine Bio-Tech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ESCRS
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Undisclosed


Lead Product(s): Talazoparib,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Pfizer Inc | Dana-Farber Cancer Institute | Memorial Sloan Kettering Cancer Center

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 25, 2025

blank

01

Prostate Cancer Clinical Trials Consortium

Country
arrow
ESCRS
Not Confirmed

Prostate Cancer Clinical Trials Consortium

Country
arrow
ESCRS
Not Confirmed

Lead Product(s) : Talazoparib,Inapplicable

Therapeutic Area : Oncology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Pfizer Inc | Dana-Farber Cancer Institute | Memorial Sloan Kettering Cancer Center

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 25, 2025

blank

Details:

Talzenna (talazoparib), an oral PARP inhibitor in combination with Xtandi (enzalutamide) is approved for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).


Lead Product(s): Talazoparib,Enzalutamide

Therapeutic Area: Oncology Brand Name: Talzenna

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 13, 2025

blank

02

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Details : Talzenna (talazoparib), an oral PARP inhibitor in combination with Xtandi (enzalutamide) is approved for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).

Product Name : Talzenna

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 13, 2025

blank
  • Development Update

Details:

Undisclosed


Lead Product(s): Atezolizumab,Talazoparib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibody

Sponsor: Genentech | Strategic Alliance

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 08, 2025

blank

03

MD Anderson Cancer Center

Country
arrow
ESCRS
Not Confirmed

MD Anderson Cancer Center

Country
arrow
ESCRS
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

January 08, 2025

blank

Details:

Talzenna (talazoparib) combined with Xtandi (enzalutamide) is approved by EMA for treating metastatic castration-resistant prostate cancer (mCRPC).


Lead Product(s): Talazoparib,Enzalutamide

Therapeutic Area: Oncology Brand Name: Talzenna

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 01, 2024

blank

04

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Details : Talzenna (talazoparib) combined with Xtandi (enzalutamide) is approved by EMA for treating metastatic castration-resistant prostate cancer (mCRPC).

Product Name : Talzenna

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 01, 2024

blank

Details:

Talzenna (talazoparib) is a PARP inhibitor, which is approved for the treatment of BRCA gene mutation-positive castration-resistant prostate cancer with distant metastases.


Lead Product(s): Talazoparib,Inapplicable

Therapeutic Area: Oncology Brand Name: Talzenna

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 02, 2024

blank

05

ESCRS
Not Confirmed
ESCRS
Not Confirmed

Details : Talzenna (talazoparib) is a PARP inhibitor, which is approved for the treatment of BRCA gene mutation-positive castration-resistant prostate cancer with distant metastases.

Product Name : Talzenna

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 02, 2024

blank

Details:

Talzenna (talazoparib) is an oral inhibitor of PARP, which plays a role in DNA damage repair combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).


Lead Product(s): Talazoparib,Enzalutamide

Therapeutic Area: Oncology Brand Name: Talzenna

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: TFS Trial Form Support

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 20, 2023

blank

06

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Details : Talzenna (talazoparib) is an oral inhibitor of PARP, which plays a role in DNA damage repair combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistan...

Product Name : Talzenna

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 20, 2023

blank

Details:

Talzenna (talazoparib) is an oral PARP inhibitor, which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to cancer cell apoptosis.


Lead Product(s): Talazoparib,Enzalutamide

Therapeutic Area: Oncology Brand Name: Talzenna

Study Phase: Phase IIIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 16, 2023

blank

07

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Details : Talzenna (talazoparib) is an oral PARP inhibitor, which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to cancer cell apoptosis.

Product Name : Talzenna

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 16, 2023

blank

Details:

Undisclosed


Lead Product(s): Talazoparib,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 14, 2022

blank

08

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Pfizer Inc

U.S.A
arrow
ESCRS
Not Confirmed

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 14, 2022

blank

Details:

CX-5461 (pidnarulex) stabilizes the DNA G-quadruplexes of cancer cells which leads to disruption of the cell's replication fork. Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1/2 and PALB2 mutations.


Lead Product(s): Pidnarulex,Talazoparib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 31, 2022

blank

09

ESCRS
Not Confirmed
ESCRS
Not Confirmed

Details : CX-5461 (pidnarulex) stabilizes the DNA G-quadruplexes of cancer cells which leads to disruption of the cell's replication fork. Pidnarulex demonstrated clinically significant and lasting benefits in patients with specific tumor biomarkers, such as BRCA1...

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 31, 2022

blank

Details:

ART4215 is first selective, oral, small molecule inhibitor of Polθ polymerase domain to enter clinic. Polθ, a DNA polymerase, is a tumor-specific DDR target involved in MMEJ that is overexpressed in many tumors and found in low levels in healthy tissue.


Lead Product(s): ART4215,Talazoparib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 08, 2022

blank

10

Artios Pharma Limited

United Kingdom
arrow
ESCRS
Not Confirmed

Artios Pharma Limited

United Kingdom
arrow
ESCRS
Not Confirmed

Details : ART4215 is first selective, oral, small molecule inhibitor of Polθ polymerase domain to enter clinic. Polθ, a DNA polymerase, is a tumor-specific DDR target involved in MMEJ that is overexpressed in many tumors and found in low levels in healthy tissue...

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 08, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for / Talazoparib API manufacturers, exporters & distributors?

Talazoparib manufacturers, exporters & distributors 1

56

PharmaCompass offers a list of Talazoparib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Talazoparib manufacturer or Talazoparib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Talazoparib manufacturer or Talazoparib supplier.

PharmaCompass also assists you with knowing the Talazoparib API Price utilized in the formulation of products. Talazoparib API Price is not always fixed or binding as the Talazoparib Price is obtained through a variety of data sources. The Talazoparib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Talazoparib

2YQ Manufacturers

A 2YQ manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 2YQ, including repackagers and relabelers. The FDA regulates 2YQ manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 2YQ API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of 2YQ manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

2YQ Suppliers

A 2YQ supplier is an individual or a company that provides 2YQ active pharmaceutical ingredient (API) or 2YQ finished formulations upon request. The 2YQ suppliers may include 2YQ API manufacturers, exporters, distributors and traders.

click here to find a list of 2YQ suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

2YQ NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 2YQ as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for 2YQ API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture 2YQ as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain 2YQ and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 2YQ NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of 2YQ suppliers with NDC on PharmaCompass.

2YQ GMP

2YQ Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of 2YQ GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 2YQ GMP manufacturer or 2YQ GMP API supplier for your needs.

2YQ CoA

A 2YQ CoA (Certificate of Analysis) is a formal document that attests to 2YQ's compliance with 2YQ specifications and serves as a tool for batch-level quality control.

2YQ CoA mostly includes findings from lab analyses of a specific batch. For each 2YQ CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

2YQ may be tested according to a variety of international standards, such as European Pharmacopoeia (2YQ EP), 2YQ JP (Japanese Pharmacopeia) and the US Pharmacopoeia (2YQ USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty